SIRT4 enhances the sensitivity of ER‐positive breast cancer to tamoxifen by inhibiting the IL‐6/STAT3 signal pathway
Abstract Recent advances in endocrine therapy have improved the prospects for estrogen receptor‐positive breast cancer. Tamoxifen is an effective drug for patients with estrogen receptor‐positive breast cancer, but the development of resistance is common. Therefore, discovering ways to enhance the s...
Main Authors: | Jilin Xing, Ji Li, Lin Fu, Junda Gai, Jingqian Guan, Qingchang Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-11-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.2557 |
Similar Items
-
SRC Promotes Tamoxifen Resistance in Breast Cancer via Up-Regulating SIRT1
by: Zhou J, et al.
Published: (2020-05-01) -
Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer
by: Ho Tsoi, et al.
Published: (2021-03-01) -
Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis
by: Huang Qiong, et al.
Published: (2021-05-01) -
Ubiquitin-Specific Peptidase USP22 Negatively Regulates the STAT Signaling Pathway by Deubiquitinating SIRT1
by: Ning Ao, et al.
Published: (2014-06-01) -
Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin
by: Lydia Brandl, et al.
Published: (2018-09-01)